Author: theo@myriadweb.com
-
ONL Therapeutics Appoints Penny Fleck as Chief Development Officer
ONL Therapeutics Appoints Penny Fleck as Chief Development Officer ANN ARBOR, Mich., January 7, 2025 – ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the appointment of Penny Fleck as chief development officer. In this role, Ms. Fleck will be responsible for…
-
ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing
ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing Funds will advance the development of ONL1204 Ophthalmic Solution with the initiation of a Phase 2 global study for the treatment of geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) ANN ARBOR, Mich., September 13, 2024 – ONL Therapeutics, Inc., a clinical-stage biopharmaceutical…
-
ONL Therapeutics to Present at the 57th Annual Scientific Meeting of The Retina Society and EURETINA Innovation Spotlight
ONL Therapeutics to Present at the 57th Annual Scientific Meeting of The Retina Society and EURETINA Innovation Spotlight ANN ARBOR, Mich., September 10, 2024 – ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the company plans to present clinical data at…
-
ONL Therapeutics To Present At 2024 BIO CEO & Investor Conference
ONL Therapeutics To Present At 2024 BIO CEO & Investor Conference ANN ARBOR, Mich., February 6, 2024 – ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, announced today that David Esposito, president and chief executive officer, will present a corporate update at the BIO CEO & Investor…
-
ONL Therapeutics to Present on ONL1204 in Podium Presentation at the 47th Annual Meeting of the Macula Society
ONL Therapeutics to Present on ONL1204 in Podium Presentation at the 47th Annual Meeting of the Macula Society The presentation will review study population data from ONL’s Phase 2 study of ONL1204 Ophthalmic Solution in patients with Macula-Off Rhegmatogenous Retinal Detachment ANN ARBOR, Mich., January 23, 2024 – ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company…
-
ONL Therapeutics Completes Enrollment in Phase 2 Study of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment
More than 135 patients recruited in four months for Phase 2 study of a single intravitreal (IVT) injection of ONL1204 Ophthalmic Solution as adjunct to standard-of-care surgery
-
ONL Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment
ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the first patient has been dosed in its Phase 2 clinical trial of ONL1204 Ophthalmic Solution in patients with macula-off rhegmatogenous retinal detachment (RRD).
-
ONL Therapeutics to Report Clinical Data on ONL1204 in Podium Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
ONL Therapeutics to Report Clinical Data on ONL1204 in Podium Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Presentation will review the results of ONL’s Phase 1 study of ONL1204 Ophthalmic Solution in patients with Macula-Off Rhegmatogenous Retinal DetachmentPreclinical data in models of inherited retinal degeneration and age-related macular degeneration…
-
ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial
ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial Funding supports Phase 2 clinical study of ONL1204 Ophthalmic Solution to evaluate safety and efficacy in patients with macula-off rhegmatogenous retinal detachment ANN ARBOR, MI – March 8, 2023 ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company…